The shareholders of Haselmeier Group sold all shares in Haselmeier Group for an enterprise value of 100 million Euros to stock exchange listed Swiss company Sulzer AG.
Haselmeier Group, founded in 1920 and headquartered in St. Gallen with a development and production centre in Stuttgart, is a leading, own-IP provider of drug delivery devices such as subcutaneous self-injection pens for use in fast-growing indications such as reproductive health, growth disorders, osteoporosis and diabetes. Haselmeier employs approximately 230 people and achieved a turnover of around 36 million Euros in 2019.
By acquiring Haselmeier, Sulzer will complement its healthcare portfolio and strengthen its applicator systems division. Together with Sulzer's financial strength and know-how in precision injection moulding, the company will seize growth opportunities in the rapidly increasing drug delivery devices market. In addition, combining Sulzer's expertise in liquid mixing applications with Haselmeier's drug delivery competence will benefit Sulzer's pharmaceutical customers by providing them with innovative and sophisticated devices and services.
The transaction has been completed on 1 October 2020 in Zurich.
An international team from CMS, led by partners Stephan Werlen (CMS Zurich) and Stefan-Ulrich Müller (CMS Munich), advised the shareholders of Haselmeier Group on all legal matters of the transaction.
- Dr Stephan Werlen, Partner, Corporate / M&A
- Pascal Stocker, Associate, Corporate / M&A
- Alexandra Stocker, Associate, Corporate / M&A
- Dr Ferdinand Blezinger, Associate, Corporate / M&A
- Stefan-Ulrich Müller, Partner, Corporate / M&A
- Felix Schmitt, Associate, Corporate / M&A